FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Mammal patents



      
           
This page is updated frequently with new Mammal-related patent applications. Subscribe to the Mammal RSS feed to automatically get the update: related Mammal RSS feeds. RSS updates for this page: Mammal RSS RSS


Implantable stoma ring

Date/App# patent app List of recent Mammal-related patents
08/28/14
20140245468
 Non-human animals with modified immunoglobulin heavy chain sequences patent thumbnailnew patent Non-human animals with modified immunoglobulin heavy chain sequences
Non-human animals, e.g., mammals, e.g., mice or rats, are provided comprising an immunoglobulin heavy chain locus that comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence. The rearranged human immunoglobulin heavy chain variable region nucleotide sequence may be operably linked to a heavy or light chain constant region nucleic acid sequence.
08/28/14
20140243910
 Bone joining apparatus and method patent thumbnailnew patent Bone joining apparatus and method
Provided is a bone joining device suitable for joining a first bone piece to a second bone piece. Also provided is a method of joining a first bone piece with a second bone piece in a living mammal.
08/28/14
20140243588
 Implantable stoma ring patent thumbnailnew patent Implantable stoma ring
The present invention relates to a ring (1) for implantation in patients receiving stoma having (i) an inner ring (2) suitable for fitting an abdominal wall on its outer circumference having an opening (3) suitable for an abdominal organ to pass through the ring to the exterior side (5) and (ii) a lip seal (4) extending over the interior side (5) of the inner ring (2) to seal the stoma opening for use in abdominal surgery. In addition, the present invention is directed to a method of treatment, comprising the surgical introduction of a ring (1) of the invention into the abdominal wall of a mammal in need of abdominal, preferably stoma surgery..
08/28/14
20140243532
 Novel precursors of glutamate derivatives patent thumbnailnew patent Novel precursors of glutamate derivatives
This invention relates to novel precursors suitable for 18f radiolabeling of glutamate derivatives, methods for preparing such compounds and its intermediates, compositions comprising such compounds, kits comprising such compounds or compositions and methods for 18f radiolabeling of glutamate derivatives wherein the obtained 18f radiolabeled glutamate derivatives are suitable for diagnostic imaging by positron emission tomography (pet) of proliferative diseases e.g. Tumor in mammals..
08/28/14
20140243520
 Pyrrolopyridines as kinase inhibitors patent thumbnailnew patent Pyrrolopyridines as kinase inhibitors
Compounds of formula i are useful for inhibition of chk1 and/or chk2. Methods of using compounds of formula i and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed..
08/28/14
20140243501
 Histone deacetylase inhibitors and synthetic method thereof and use thereof in manufacture of medicaments patent thumbnailnew patent Histone deacetylase inhibitors and synthetic method thereof and use thereof in manufacture of medicaments
The invention provides histone deacetylase (hdac) inhibitors shown as formula i, where r1 to r8 are as defined in the specification. The invention also provides methods for synthesis of these compounds and applications of these compounds in preparing pharmaceuticals for preventing or treating mammal diseases related to the dysregulation of hdac..
08/28/14
20140243401
 Methods of screening compounds that are cytotoxic to tumor cells and methods of treating tumor cells using such compound patent thumbnailnew patent Methods of screening compounds that are cytotoxic to tumor cells and methods of treating tumor cells using such compound
The invention relates to methods of screening to find compounds that are cytotoxic to tumor cells and methods of treating tumor cells using these compounds. In particular, the invention relates to methods of screening for compounds that inhibit mammalian mitochondrial fatty acid synthase (mmfas) and methods of treating tumor cells using mmfas inhibitors.
08/28/14
20140243318
 Salts and polymorphs of 8-fluoro-2--1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one patent thumbnailnew patent Salts and polymorphs of 8-fluoro-2--1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(adp-ribose) polymerase activity including the disease condition such as cancer..
08/28/14
20140243313
 Tricyclic compounds useful as neurogenic and neuroprotective agents patent thumbnailnew patent Tricyclic compounds useful as neurogenic and neuroprotective agents
The invention disclosed herein is direct to compounds of formula i and pharmaceutically acceptable salts thereof, which are useful in treating neurodegenerative diseases and promoting the generation or survival of neurons in the mammalian brain. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of formula i or a pharmaceutically acceptable salt thereof.
08/28/14
20140243272
 Compound and method for treatment of alzheimer's disease patent thumbnailnew patent Compound and method for treatment of alzheimer's disease
An isolated protein selected from the group consisting of (i) proteins comprising an amino acid sequence having at least 70% identity to the c-terminal domain of lung surfactant protein c precursor (ctprosp-c, “ctc”) from a mammal; and (ii) proteins comprising an amino acid sequence having at least 70% identity to the brichos domain of ctprosp-c from a mammal, is disclosed for treatment of alzheimer's disease in a mammal, including man.. .
08/28/14
20140243258
new patent Methods and compositions for targeting adipose cells in mammals
Methods and compositions are presented for use in diagnostic, imaging or targeting of therapeutic agents to treat obesity/adiposity-associated disorders, where such as compositions and methods identify and use peptides to selectively target adipose tissue stromal cells in mammals, both in vitro and in vivo.. .
08/28/14
20140242692
new patent Mammalian genes involved in toxicity and infection
The present invention relates to cellular proteins that are involved in toxicity and infection or are otherwise associated with the life cycle of one or more pathogens.. .
08/28/14
20140242347
new patent Graft for directed vascular and lymphatic regeneration and methods to guide endothelial cell assembly
Embodiments of the present invention relate to a therapeutic device (graft) comprising a collagen membrane having an aligned uniaxial or biaxial structure such that mammalian cells plated on the membrane align mainly along the direction of the collagen fibrils. In a further aspect, a graft comprising a substantially tubular body, wherein the body has an exterior surface, an interior surface, and at least one lumen extending therethrough such that a fluid flow through the lumen can direct mammalian cell migration.
08/28/14
20140242139
new patent Controlled drug delivery
A medical device for placement in a body of a mammal is provided. The medical device comprises (1) a polymeric matrix forming the device and defining a lumen through the device, the matrix comprising polymer macromolecules and defining spaces between the polymer macromolecules; (2) a drug contained within at least some of the spaces of the matrix; and (3) a material contained within at least some of the spaces of the matrix to affect diffusion of the drug out of the polymeric matrix when the medical device is placed in the body of the mammal..
08/28/14
20140242111
new patent Engineered bacteria for oral delivery of glucoregulatory proteins
Disclosed is an oral delivery system that overcomes major barriers encountered in the gastrointestinal tract, particularly rapid proteolytic degradation and low intestinal permeability. Provided is a method for oral delivery of an engineered microorganism to a mammal where the microorganism produces a macromolecule having a desired bioavailability outcome..
08/28/14
20140242093
new patent Methods and compositions for modulating the innate immune response and/or myogenesis in a mammalian subject
In one aspect, the present invention relates to methods for increasing, decreasing or maintaining the innate immune response in a mammalian subject comprising modulating the expression of dux4-fl, or modulating the expression of beta-defensin 3 (defb103). In another aspect, the present invention relates to methods for increasing, decreasing or maintaining myogenesis or muscle differentiation in a mammalian subject comprising modulating the expression of beta-defensin 3 (defb103).
08/28/14
20140242089
new patent Glycoproteins having lipid mobilising properties and therapeutic applications thereof
A biologically active lipid mobilising agent for use in therapy is disclosed which has the properties and characteristics of a zn-α2-glycoprotein, or of a fragment thereof having an apparent molecular mass mr greater than 6.0 kda as determined by gel exclusion chromatography. Methods of isolation and purification from biological material are also disclosed together with uses of the material for making up pharmaceutical compositions, especially pharmaceutical compositions useful for treating mammals to achieve weight reduction or for controlling obesity.
08/28/14
20140242018
new patent Liquid non-ionic salt-free skin and hair treatment composition that contains n-methyl lauroyl glucamide
Compositions and methods for of their use in treating human or other mammalian skin and hair. Non-ionic, salt-free non-solidifying formulations of lauroyl n methyl-c10, c12, c14, c16 alkanoyl-n-methyl-glucamide and alkyl glycosides are disclosed that impart beneficial barrier properties to skin and hair..
08/28/14
20140242009
new patent Bioactive compositions from theacea plants and processes for their production and use
The present invention relates to isolated bioactive compositions containing bioactive fractions derived from theacea plants. The present invention also relates to bioactive topical formulations containing the bioactive compositions.
08/28/14
20140241986
new patent Formulations of fluorinated stilbene suitable for pet imaging
The invention is directed to formulations of lipophilic amyloid beta ligand stilbene and more particularly to formulations which are capable to be administered parenterally e.g. Intravenously, wherein the lipophilic amyloid beta ligand stilbene is a fluorinated stilbene.
08/21/14
20140237630
Screening method
The present invention provides a method of screening a mammal for the onset or predisposition to the onset of a neuropsychiatric disorder. More particularly, the present invention provides a method of screening a mammal for the onset or predisposition to the onset of schizophrenia by screening for a decrease in the functional level of protein 14-3-3ζ.
08/21/14
20140235924
Method of radiotherapy
The invention provides a method for the treatment of soft tissue disease in a mammalian subject (preferably a human or canine subject), said method comprising administering to said subject a therapeutically effective quantity of a soft tissue targeting complex of thorium-227 and a complexing agent, wherein said quantity is such that an acceptably non-myelotoxic quantity of radium-223 is generated in vivo by nuclear decay of the administered thorium-227.. .
08/21/14
20140235735
Protein damage in aging and age-related diseases
The process of aging and the development of age-related diseases are related to the emerging phenotypes of increasingly damaged and progressively malfunctioning proteomes. The present invention provides methods of preventing aging and age-related diseases in mammals by assessment of protein-specific oxidative damage.
08/21/14
20140235688
Treatment of external parasites by oral administration of parasiticidal agents
Pharmaceutically acceptable compositions of fipronil for oral delivery to mammals and methods for use of the compositions to control external parasites, such as fleas and ticks.. .
08/21/14
20140235681
Combination therapy for glaucoma
Disclosed herein is method of treating glaucoma or ocular hypertension comprising administering a prostaglandin agonist and a second therapeutically active agent to a mammal in need thereof, wherein said second therapeutically active agent is selected from: β-blockers, adrenergic agonists, non-selective adrenergic agonists, α2-selective adrenergic agonists, carbonic anhydrase inhibitors, cholinergic agonists, direct acting cholinergic agonists, chlolinesterase inhibitors, glutamate antagonists, ca2+ channel blockers, prostamides, prostaglandins, cannabinoids, and combinations thereof. Compositions and medicaments containing a combination of these two active agents are also disclosed..
08/21/14
20140235649
Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
A method of treating a mammalian subject afflicted with a disease characterized by a loss of protein function caused by a genetic abnormality associated with the disease comprising administering to the subject a therapeutically effective amount of a protein phosphatase 2a inhibitor or a histone deacetylase inhibitor.. .
08/21/14
20140235619
Agents and methods for treating ischemic and other diseases
This invention relates to methods of screening for modulators of mammalian cell injury cause by trpm7 gene and protein activity, compounds that modulate trpm7 gene and protein activity and methods of treatment of mammalian cell injury using modulators of trpm7 gene and protein activity.. .
08/21/14
20140235601
Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males
The use of an aromatase blocker or an estrogen blocker is described in a method for increasing spermatogenesis and seritolli cell function, and/or improving leydig cell function, in order to to increase endogenous testosterone levels in a male mammal. The levels of active materials used are significantly lower than the levels of these materials used to treat female estrogen sensitive tumors..
08/21/14
20140235564
Methods for treating neural cell swelling
A composition comprising a novel ca2+-activated, [atp]i-sensitive nonspecific cation (ncca-atp) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [ca]i.
08/21/14
20140235554
Ophthalmic formulation derived from silk protein
An ophthalmic composition is described for the treatment of dry eye syndrome in a human or mammal. The composition comprises an aqueous solution including an effective amount of silk protein.
08/21/14
20140235544
Disease treatment via antimicrobial peptides or their inhibitors
The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (amp) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous amps or that compete with pro-inflammatory agents or fragments of amps on cognate receptors without inducing disease..
08/21/14
20140235529
Aromatic-cationic peptides and methods for using same
The present disclosure provides methods of preventing or treating renal ischemia-reperfusion injury in a mammalian subject and methods for chronic treatment of arvd, including administering an effective amount of an aromatic-cationic peptide to a subject in need thereof. The methods include administering aromatic-cationic peptides to prevent or treat renal injury during the treatment of renal artery stenosis.
08/21/14
20140234966
Albumin formulation and use
The invention relates to a new formulation of albumin, a method for producing the albumin formulation and to uses of the albumin formulation, for example in cell culture such as mammalian cell culture and particularly in stem cell culture.. .
08/21/14
20140234965
Triazine derivatives as differentiation catalysts
A method of inducing differentiation of mammalian cells into cardiomyocyte-like cells by contacting the mammalian cell with a triazine compound of formula (i), wherein x is independently —nr4— or —o—, r4 is hydrogen or c1-6-alkyl; r1 is hydroxy, c1-6-alkyl, c1-6-alkoxy, carboxy, c1-6-alkoxycarbonyl, halo, cyano, nitro, formyl, amino, c1-6-alkylamino, or di-c1-6-alkylamino, the c1-6-alkyl or -alkoxy residue being optionally substituted with one or more r5 substituents selected from hydroxy, halo, cyano, and nitro; n is 0 to 5; r2 is hydrogen, aryl, heteroaryl, or c1-6-alkyl, the aryl or heteroaryl residue being optionally substituted with one or more r1 substituents, and where the c1-6-alkyl is optionally further substituted with one or more r5 substituents; and r3 is selected from hydrogen, halo, nr4r7, or7, sr7, and r7, where the same options apply for r7 as for r2; with the proviso that the compound of formula (i) is not 3-[(4,6-diphenoxy-1,3,5-triazin-2-yl)amino]benzoic acid.. .
08/21/14
20140234957
Engineered cellular pathways for programmed autoregulation of differentiation
The present invention provides compositions and methods for programming mammalian cells to perform desired functions. In particular, the present invention provides compositions and methods for programming stem cells to differentiate into a desired cell type.
08/21/14
20140234905
Cell culture improvements
The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture..
08/21/14
20140234888
Method for improved selection of therapeutic agents
The current invention comprises a method of selection of therapeutic agents for treatment of a particular disease in humans or other mammals in which the ratio of the concentrations of thiol (—sh) and disulfide (—ss—) groups is determined in the blood. The therapeutic agent to be tested may be used to treat a neoplastic, infectious, immunological, inflammatory, or other disorder that involves (but is not limited to) the following physiological systems: respiratory, cardiovascular, genitourinary, gastrointestinal (including the liver and pancreas), neurological, musculoskeletal, immunological, and skin..
08/21/14
20140234863
Immunoassay methods
The invention relates to a method of detecting a disease state or disease susceptibility in a mammalian subject which comprises detecting an antibody in a test sample comprising a bodily fluid from said mammalian subject wherein said antibody is a biological marker of a disease state or disease susceptibility, the method comprising: (a) contacting said test sample with a plurality of different amounts of an antigen specific for said antibody, (b) detecting the amount of specific binding between said antibody and said antigen, (c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a) and (d) determining the presence or absence of said disease state or disease susceptibility based upon the amount of specific binding between said antibody and said antigen at each different antigen concentration used.. .
08/21/14
20140234837
Epigenetic marker for the identification of natural killer cells
The present invention relates to a method, in particular an in vitro method for identifying a subgroup of natural killer cells of a mammal, preferably cd3−, non t-lymphocyte derived nk cells, which often express the surface proteins cd56 and/or cd16, comprising analyzing the accessibility of the genomic dna for osbpl, such as osbpl5, to bisulfite conversion and/or the methylation status of at least one cpg position in the genes for osbpl, such as osbpl5, in particular in their upstream and/or downstream regulatory regions, the promoter, introns, exons and introns exon borders and other conserved regions of said genes, wherein an increase of the accessibility of the genomic dna and/or a demethylation in the sample as analyzed is indicative for said subgroup of nk cells. The analyses according to the invention can identify cd56+ cells and distinguish them from all other cells such as, for example, either cd56− and/or cd56 bright cells.
08/21/14
20140234407
Method for increasing lactose tolerance in mammals exhibiting lactose intolerance
The method for increasing lactose tolerance in subjects exhibiting lactose intolerance symptoms implements a protocol where the subjects ingest a gradually increasing amount of lactose containing product over a six week period. At various points during the six week period the subject ingests the lactose containing product once a day and then twice a day.
08/21/14
20140234400
Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells
A method of preferentially delivering an active agent to an immune cell, such as a myeloid progenitor cell, a dendritic cell, a monocyte, a macrophage or a t-lymphocyte, or other cell type restricted to a functional organ system or an anatomic entity, of a mammalian subject by administering a lipid-drug complex to the subject. The lipid-drug complex is comprised of an active agent, such as a drug, and an outer surface with a targeting ligand that binds a marker on the surface of the immune cell or other cell type that is infected with or susceptible to infection with an infectious agent.
08/21/14
20140234398
Dissolution of arterial plaque
Some embodiments of the present invention provide pharmaceutical formulations, for treating atherosclerosis in a mammal, including a bile acid and/or a terpene atherosclerotic plaque emulsifier. Some embodiments provide methods for administering such pharmaceutical formulations.
08/21/14
20140234378
Lobster hemolymph as a utility for treatment of mammalian tissue lesions
The invention is crustacean hemolymph as a utility for the pharmaceutical and/or cosmetic treatment of viral and other neoplastic or pre-neoplastic mammalian tissue lesions. The method comprises topically administering to mammalian tissue a formula that is made from lobster hemolymph—neat; or lobster hemolymph extracts; or lobster hemolyph in combination with certain carriers, binders; or as an adjuvant.
08/21/14
20140234361
Novel expression vectors and uses thereof
A method for treating an hiv disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a dna vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a dna sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a dna binding domain which binds to a specific dna binding sequence, and (ii) a functional domain of the bovine papilloma virus type 1 e2 protein, where the functional domain binds to a nuclear component; (b) a multimerized dna sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a dna sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells.. .
08/21/14
20140234342
Nkp46-mediated nk cell tuning
The present invention relates to compounds (e.g. Antibodies) that specifically bind and inhibit nkp46.
08/21/14
20140234322
Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
Disclosed are transgenic non-human mammals, which useful for the screening of thrombopoietin mimetics, thrombopoietin receptor agonists, or thrombopoietin receptor antagonists active on the human thrombopoietin receptor. The transgenic non-human mammal has a genome that comprises a stably integrated transgene construct comprising a polynucleotide sequence encoding a humanized thrombopoietin receptor wherein said transgenic non-human mammal has a baseline blood platelet count corresponding to a physiological blood platelet count of a matched non-transgenic non-human mammal.
08/21/14
20140234299
Therapies for chronic renal failure using one or more integrin antagonists
The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain integrin antagonists..
08/21/14
20140234297
Antibody constant domain regions and uses thereof
The invention provides recombinant protein (e.g., a recombinant antibody or soluble receptor) having (i) a binding domain capable of specific binding to an epitope (for example an antibody variable domains, a receptor, a growth factor, a cytokine, or a fragment of any of the foregoing which is capable of specifically binding the desired epitope) and (ii) an effector domain comprising a constant domain region which is derived from immunoglobulin of a first species which is a companion mammal, e.g. Dog, cat, or horse, having engineered substitutions at one or more positions and having an altered interaction with one or more fcrs or other ligands, and optionally enhanced effector function, relative to the parent constant domain region..
08/21/14
20140234286
Skeletal muscle regeneration promoter
Provided is a skeletal muscle regeneration promoter for a muscular disorder or myopathy comprising a chondroitinase as an active component, which skeletal muscle regeneration promoter enhances, when administered into a muscular fiber of a mammal with the muscular disorder or myopathy, the regeneration of such a muscular fiber. The above-mentioned chondroitinase degrades chondroitin sulfate that is present at the outer perimeter of the above-mentioned muscular fiber; and thereby inhibition of the regeneration of the muscular fiber by the above-mentioned chondroitin sulfate disappears, which makes it possible to enhance the regeneration and enlargement of such a muscular fiber..
08/21/14
20140234260
Compositions and methods for probiotic recolonization therapies
The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of bacteroides, eubacteria, fusobacteria, propionibacteria, lactobacilli, anaerobic cocci, ruminococcus, e.
08/21/14
20140234256
Commensal bacteria as signal mediators within a mammalian host
Genetically engineered cells and microorganisms are provided for preventing or ameliorating diseases through genetically engineered quorum signaling. Therapeutic methods for using the cells and microorganisms to prevent or ameliorate diseases are also provided.
08/21/14
20140234254
Heteroaromatic compounds as pi3 kinase modulators and methods of use
The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (pi3 kinases) and mtor, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans..
08/21/14
20140234250
Methods and compositions for improving appearance and formation of scar tissue
This invention relates to methods and compositions for degrading collagen in mammalian skin, thereby improving the appearance and/or reducing the size of a closed wound, which may be a scar or a keloid and cellulite or other conditions wherein excessive collagen is a problem.. .
08/21/14
20140234249
Methods and compositions for improving appearance and formation of scar tissue
This invention relates to methods and compositions for degrading collagen in mammalian skin, thereby improving the appearance and/or reducing the size of a closed wound, which may be a scar or a keloid and cellulite or other conditions wherein excessive collagen is a problem.. .
08/14/14
20140229115
Methods for diagnosing diseases and evaluating treatments therefor using pet
The present invention relates to methods for determining whether a mammal has a disease, such as diabetes, using pet data analysis techniques. These methods include administering to a mammal a pet-compatible tracer, such as a radioligand specific for a vesicular monoamine transporter 2 (vmat2) receptor, and measuring total functional β-cell capacity (volume) of the mammal's pancreas using pet data analysis techniques.
08/14/14
20140228917
Heat recovering system for light therapy device
The invention relates to a radiation emitting device (1) for application near mammal tissue (2), comprising: a substrate (3) having a front surface (4) and an opposing back surface (5), said substrate accommodating at least one radiation source (6) on said front surface (4). Said at least one radiation source (6) is arranged for applying energy on said mammal tissue (2).
08/14/14
20140228875
Surgical device with integrated visualization and cauterization
Surgical devices with integrated visualization and cauterization are described herein where such devices include an elongate structure having a central lumen and an expandable space-creating structure having at least one expandable leaflet mounted in the vicinity of the distal end and is configured for placement within a mammalian body proximate to a therapeutic target. Also included is a proximal terminal having an actuator mounted in the vicinity of the proximal end and is configured to remain outside of said body and provide an actuation mechanism for actuating the space-creating structure.
08/14/14
20140228818
Urethral catheter tension holding and movement stabilizing devices
This document provides methods and materials involved in holding tension on a urethral catheter and/or stabilizing the movement of a urethral catheter. For example, devices configured to allow a physician to hold tension on a urethral catheter and stabilize movement of a urethral catheter at the urethral meatus in a mammal (e.g., a human) in a non-invasive manner as well as methods for using catheter tension holding and movement stabilizing devices are provided..
08/14/14
20140228790
Wound dressing with a discontinuous contact layer surface
A therapeutic device for promoting the healing of a wound in a mammal is disclosed. An exemplary device comprises a permeable structure having a plurality of depressions formed in a surface thereof.
08/14/14
20140228764
Catheter with variable attachment means
The invention relates to a design for securing tubes, catheters, drains, or other tubular medical devices within the body of a mammal, for example a human, and methods of securing same. The invention includes a first tubular body and at least one second tubular body.
08/14/14
20140228431
Method of treating constipation
Disclosed is a method of manipulating the rate of gastrointestinal transit in a mammalian subject. Also disclosed is the use, in the manufacture of a medicament for the treatment of constipation, of a selective inhibitor of methanogensis, a methanogen-displacing probiotic agent, or a prebiotic agent that inhibits the growth of methanogenic bacteria or promotes the growth of competing non-methanogenic intestinal flora.
08/14/14
20140228361
Aminoquinazoline derivatives and their salts and methods of use
The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling.
08/14/14
20140228319
Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications
The present invention relates to pharmaceutically acceptable water soluble salts of aldose reductase inhibitors, 2-(8-oxo-7-((5-trifluromethyl)-1h-benzo[d]imidazol-2-yl)methyl)7,8-dihydropyrazin[2,3-d]pyridazin-5-yl)acetic acid and [4-oxo-(5-trifluoromethyl-benzothaiazol-2-ylmethyl)-3,4-dihydro-phthalazin-1-yl]-acetic acid (also known as zopolrestat), pharmaceutical compositions thereof and methods of treating diabetic complications in mammals comprising administering to mammals these salt and compositions.. .
08/14/14
20140228294
Natriuretic polypeptides with unique pharmacologic profiles
This document provides natriuretic polypeptides. For example, this document provides polypeptides having a natriuretic activity.
08/14/14
20140228287
1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-axanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal
A pharmaceutical composition includes 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine or a pharmaceutically acceptable form thereof as pharmaceutically active compound for the therapy of a metabolic disorder or metabolic disease of a predominantly carnivorous non-human animal. It is especially useful for the therapy of diabetes and related diseases of predominantly carnivorous mammals like cats or dogs.
08/14/14
20140227703
Epigenetic marker for the identification of il17 positive t cells in complex samples
The present invention relates to a method, in particular an in vitro method for identifying il-17 expressing t cells in a blood and/or tissue sample derived from a mammal, comprising analysing the methylation status of at least one cpg position in the gene il-17a, wherein a demethylation of said at least one cpg position in said sample when compared to an analogous position in a non il-17 blood cell is indicative for a il-17 positive cd4 positive t cell. The analyses according to the invention can identify il-17 positive t cells and distinguish them from all other cells in complex samples, such as, for example, other blood cells.
08/14/14
20140227361
Cross-linked hyaluronic acid and collagen and uses thereof
The present invention discloses a cross-linked hyaluronic acid/collagen formulation which has improved composition for dermal filling and higher persistence than cross-linked collagen or ha alone. Also disclosed are methods for preparing cross-linked hyaluronic acid/collagen formulations and using such for augmenting soft tissues in mammals..
08/14/14
20140227290
Method for increasing n-glycosylation site occupancy on therapeutic glycoproteins produced in pichia pastoris
Described is a method for increasing the n-glycosylation site occupancy of a therapeutic glycoprotein produced in recombinant host cells modified as described herein and genetically engineered to express the glycoprotein compared to the n-glycosylation site occupancy of the therapeutic glycoprotein produced in a recombinant host cell not modified as described herein. In particular, the method provides recombinant host cells that overexpress a heterologous single-subunit oligosaccharyltransferase, which in particular embodiments is capable of functionally suppressing the lethal phenotype of a mutation of at least one essential protein of the yeast oligosaccharyltransferase (otase) complex, for example, the leishmania major stt3d protein, in the presence of expression of the host cell genes encoding the endogenous otase complex.
08/14/14
20140227280
Protein complex comprising mcm8 and mcm9 proteins and their use
The composition includes either an isolated protein complex including mcm8 and mcm9 proteins, or nucleic acid molecules coding for the proteins that constitute the complex, or compounds inhibiting the formation and/or the stability, or the activity of the complex, for its use for enhancing or reducing animal, preferably mammal, fertility.. .
08/14/14
20140227272
Anti-leukocyte adhesion for the mitigation of potential adverse events caused by cd3-specific binding domains
The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian t-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of t-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of t-cells against target cells are also contemplated..
08/14/14
20140227269
Therapeutic nuclease compositions and methods
Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.. .
08/14/14
20140227267
Bovine fusion antibodies
Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (cdr3h) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the cdr3h.
08/14/14
20140227261
Use of omega fatty acids for treating disease
Eicosapentaenoic acid (epa) and docosahexaenoic acid (dha), or a salt or an ester thereof, are provided for use in the treatment and/or prophylaxis of a condition selected from macular oedema, conditions causing damage to retinal photoreceptors and/or retinal pigment epithelial cells, and dry eyes in a mammal, wherein the combined dosage of eicosapentaenoic acid and docosahexaenoic acid is from 5 mmol to 25 mmol per day, and wherein the molar ratio of eicosapentaenoic acid to docosahexaenoic acid is in the range of from 1:1 to 5:1. Compositions comprising epa and dha and at least one pharmaceutically acceptable excipient, and kits containing epa, dha and further therapeutic agents are also provided.
08/14/14
20140227254
Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase i (alk1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of bmp9 and/or bmp10, ligands for alk1, may also be used to inhibit angiogenesis in vivo..
08/14/14
20140227235
Cartilage cell treatment comprising collagen, hyaluronic acid derivative, and stem cell derived from mammal umbilical cord
The present invention relates to a medical composite biomaterial. More specifically, the present invention relates to a medical composite biomaterial including collagen and a hyaluronic acid derivative.


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Mammal for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Mammal with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.5687

3196

0 - 1 - 76